Methods for Treating Vascular Leak Syndrome and Cancer

Abstract

Disclosed are methods for treating Vascular Leak Syndrome and preventing cancer metastasis. Further disclosed are methods for treating vascular leakage due to inflammatory diseases, sepsis, cancer or the presence of pathogens.

1 . A method for treating or preventing vascular leak syndrome in a patient comprising administering to the patient a composition comprising an effective amount of an HPTPO-ECD binding agent or a pharmaceutically acceptable salt thereof. 
     
     
         2 . The method according to  claim 1 , wherein the HPTPβ-ECD binding agent, or a pharmaceutically acceptable salt thereof, is administered in combination with an additional therapeutic agent, wherein the HPTPβ-ECD binding agent or pharmaceutically acceptable salt are administered together or in any order. 
     
     
         3 . The method according to  claim 1 , wherein the patient is suffering from an inflammatory disease or condition, cancer, trauma, shock, sepsis, adult respiratory distress syndrome, acute lung injury, or infection with a pathogen. 
     
     
         4 . The method according to  claim 3 , wherein the HPTPβ-ECD binding agent, or a pharmaceutically acceptable salt thereof, is administered in combination with an additional therapeutic agent, wherein the HPTPβ-ECD binding agent or pharmaceutically acceptable salt are administered together or in any order. 
     
     
         5 . The method according to  claim 4 , wherein the additional therapeutic agent is IL-2. 
     
     
         6 . The method according to  claim 4 , wherein patient is suffering from cancer and the additional therapeutic agent is a chemotherapeutic agent. 
     
     
         7 . The method according to  claim 4 , wherein the patient suffering from an infection with a pathogen and the additional therapeutic agent is an anti-pathogenic agent. 
     
     
         8 . The method according to  claim 7 , wherein the pathogen is a bacterium, a virus, or a fungus. 
     
     
         9 . The method according to  claim 8 , wherein the anti-pathogenic agent is an antibacterial agent, an antiviral agent, an anti-fungal agent, or any combination thereof. 
     
     
         10 . The method according to  claim 1 , wherein the dose of the HPTPβ-ECD binding agent, or pharmaceutically acceptable salt thereof, is from about 0.01 mg/kg to about 10 mg/kg by weight of the patient. 
     
     
         11 . The method according to  claim 1 , wherein the dose is administered once daily, three-times weekly, twice weekly, once weekly, three times monthly, twice monthly, once monthly, and once every other month. 
     
     
         12 . The method according to  claim 1 , wherein the HPTPβ-ECD binding agent is conjugated to a vehicle. 
     
     
         13 . The method according to  claim 1 , wherein the HPTPβ-ECD binding agent is administered by intravenous injection or subcutaneous injection 
     
     
         14 . A method for determining the course of treatment for a patient suffering from vascular leak syndrome, comprising:
 a) administering to a patient a composition comprising an effective amount of an HPTPβ-ECD binding agent;   b) monitoring the level of angiopoietin-2 present in the patient during the course of treatment; and   c) discontinuing treatment when the angiopoietin-2 level returns to within a normal range.   
     
     
         15 . A method for treating or preventing metastasis in a patient with cancer, by administering to a patient having cancer, a composition comprising an effective amount of an HPTPβ-ECD binding agent or a pharmaceutically acceptable salt thereof. 
     
     
         16 . The method according to  claim 15 , wherein the HPTPβ-ECD binding agent or a pharmaceutically acceptable salt thereof, is administered in combination with an additional therapeutic agent wherein the HPTPβ-ECD binding agent or pharmaceutically acceptable salt are administered together or in any order. 
     
     
         17 . The method according to  claim 16 , wherein the additional therapeutic agent is a chemotherapeutic agent. 
     
     
         18 . The method according to  claim 17 , wherein the HPTPβ-ECD binding agent is administered before the chemotherapeutic agent. 
     
     
         19 . The method according to  claim 15 , wherein the dose of the HPTPβ-ECD binding agent, or pharmaceutically acceptable salt thereof, is from about 0.01 mg/kg to about 10 mg/kg by weight of the patient. 
     
     
         20 . The method according to  claim 15 , wherein the dose is administered once daily, three-times weekly, twice weekly, once weekly, three times monthly, twice monthly, once monthly, and once every other month. 
     
     
         21 . The method according to any one of  claims 15 , wherein the HPTPβ-ECD binding agent is conjugated to a vehicle. 
     
     
         22 . The method according to  claim 15 , wherein the HPTPβ-ECD binding agent is administered by intravenous injection or subcutaneous injection. 
     
     
         23 . A method for stabilizing the vasculature of a patient in need thereof, comprising administering to the patient a composition comprising an effective amount of an HPTPβ-ECD binding agent or a pharmaceutically acceptable salt thereof. 
     
     
         24 . The method of  claim 23 , wherein the HPTPβ-ECD binding agent is administered prior to the patient undergoing a surgical treatment. 
     
     
         25 . The method of  claim 23 , wherein the HPTPβ-ECD binding agent is administered prior to the patient undergoing chemotherapeutic treatment.